These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 21217773)

  • 1. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
    Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
    Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
    Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
    BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
    Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
    Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing's sarcoma cells, interacts with the EWS-FLI1 and partner proteins.
    Thangaretnam KP; Gopisetty G; Ramanathan P; Rajkumar T
    Sci Rep; 2017 Aug; 7(1):7172. PubMed ID: 28775288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
    Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
    Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
    Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
    Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
    Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
    Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
    Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
    Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
    Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
    Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular function map of Ewing's sarcoma.
    Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
    PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
    Ban J; Siligan C; Kreppel M; Aryee D; Kovar H
    Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
    Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
    Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
    Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
    Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promiscuous partnerships in Ewing's sarcoma.
    Sankar S; Lessnick SL
    Cancer Genet; 2011 Jul; 204(7):351-65. PubMed ID: 21872822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
    Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
    Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
    Uren A; Toretsky JA
    Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.
    Sengupta A; Rahman M; Mateo-Lozano S; Tirado OM; Notario V
    Int J Oncol; 2013 Sep; 43(3):803-12. PubMed ID: 23857410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
    Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
    Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma.
    Ban J; Bennani-Baiti IM; Kauer M; Schaefer KL; Poremba C; Jug G; Schwentner R; Smrzka O; Muehlbacher K; Aryee DN; Kovar H
    Cancer Res; 2008 Sep; 68(17):7100-9. PubMed ID: 18757425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
    Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
    J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.